VivoSeq
Other

Myelosuppression

6

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Myelosuppression is an early-stage landscape with 6 programs across 4 companies. The most active players are Careseng Biotech Co., Ltd., Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Roche.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Careseng Biotech Co., Ltd.

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSCell therapy113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Recruiting2 · 33%
Unknown status1 · 17%
Withdrawn1 · 17%

Clinical Trials

Trial Activity

6 trials

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Recruiting·—·Phase 2·NCT06490081·40 enrolled
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Recruiting·FFudan University·Phase 2·NCT06699472·22 enrolled
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00482261·150 enrolled
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000691·156 enrolled
Careseng 1370 for Chemotherapy-Induced Myelosuppression
Withdrawn·CCareseng Biotech Co., Ltd.·Phase 1/2·NCT03692780
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1/2·NCT05672420·181 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)